1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Agenovir: Using Gene Editing To Kill Viral DNA

 
• By Mandy Jackson

Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.

Emerging Company Profile Regular column feature image Version 2

Agenovir Corp. won't use gene-editing to cut out defects or add in missing pieces in a patient's genome like most companies that are working with CRISPR/Cas9 constructs. Instead, it will use the technology to kill DNA that sits in latent viral reservoirs.

South San Francisco-based Agenovir believes that it has carved out a unique niche in the gene-editing space. The company's lead...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Biohaven Resorts To Cost-Cutting After Troriluzole Hit With FDA CRL

 
• By Jessica Merrill

The regulatory setback comes as a blow because troriluzole was set to be Biohaven’s sole near-term revenue generator.

Q3 Korean Biotech Roundup: Obesity News, AimedBio Deal Raise Hopes

 
• By Jung Won Shin

Alteogen's preparations to move its stock listing, ABL Bio's injection of funds into its US subsidiary to progress clinical trials and Ensol's plans for a Phase III trial of its osteoarthritis contender are among key recent developments in Korean biotech.

AAVantgarde Adds To Eye Disease Gene Therapy Trend With $141m Fundraising

 
• By Andrew McConaghie

While other gene therapies disease areas have fallen out of favor, eye disease candidates seem to be attracting more funding. Italy-based AAVantgarde is the latest to achieve a mega-round.

Japanese Bioclusters Aim To Build Communities For Global Success

 
• By Lisa Takagi

Japan's leading bioclusters tell a session at BioJapan that building a tight-knit community will help better connect different players in the startup ecosystem and help ventures grow and expand internationally.

More from Business

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.